TSE:GEN GeneNews (GEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About GeneNews Stock (TSE:GEN) 30 days 90 days 365 days Advanced Chart Get GeneNews alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume473,147 shsAverage Volume1.48 million shsMarket CapitalizationC$25.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGeneration Uranium Inc. engages in the exploration and development of mineral properties. It has an option agreement to acquire a 60% interest in the Arlington property that comprises five mineral claims located in the Arrow Boundary District of south-central British Columbia, Canada; and holds a 100% interest in the YATH Uranium Property comprises five mineral claims that totaling approximately 8,438 hectares located in the territory of Nunavut. The company was formerly known as Generation Gold Corp. and changed its name to Generation Uranium Inc. in January 30, 2024. Generation Uranium Inc. was incorporated in 2018 and is based in Vancouver, Canada.Read More… Receive GEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter. Email Address GEN Stock News HeadlinesGeneNews: Q1 Earnings SnapshotMay 16, 2024 | washingtonpost.comVertex, Crispr Get Second FDA Approval for Gene TherapyJanuary 18, 2024 | msn.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.May 4, 2025 | Altimetry (Ad)Gene-editing treatment from Vertex and CRISPR cleared for second rare blood disorderJanuary 17, 2024 | msn.comFDA expands use of newly approved CRISPR therapyJanuary 17, 2024 | msn.comOhio St hires Texas A&M athletic director Ross Bjork to replace the retiring Gene SmithJanuary 16, 2024 | washingtonpost.comMutated gene thought to exist in just 4% of people could ‘help tackle obesity’November 27, 2023 | msn.comSickle-Cell Treatment Created With Gene Editing Wins U.K. ApprovalNovember 18, 2023 | nytimes.comSee More Headlines GEN Stock Analysis - Frequently Asked Questions How do I buy shares of GeneNews? Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of GeneNews own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneNews investors own include MARA (MARA), Ocugen (OCGN), Spero Therapeutics (SPRO), American Airlines Group (AAL), First Majestic Silver (AG) and Antibe Therapeutics (ATE). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Diagnostics & Research Sub-IndustryComputer Software Current SymbolTSE:GEN CIKN/A Webwww.genenews.com Phone+1-905-7392030FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.05 Sales & Book Value Annual SalesC$234,592.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow145.00 Book ValueC($0.06) per share Price / BookN/AMiscellaneous Outstanding Shares169,963,000Free FloatN/AMarket CapC$25.49 million OptionableNot Optionable BetaN/A A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (TSE:GEN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneNews Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneNews With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.